Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors - Scorecard - MDSpire

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • By

  • Natalie Arnold

  • Alina Goßling

  • Benjamin Bay

  • Jessica Weimann

  • Christopher Blaum

  • Fabian J Brunner

  • Marco M Ferrario

  • Paolo Brambilla

  • Giancarlo Cesana

  • Valerio Leoni

  • Luigi Palmieri

  • Chiara Donfrancesco

  • Teresa Padró

  • Jonas Andersson

  • Pekka Jousilahti

  • Francisco Ojeda

  • Tanja Zeller

  • Allan Linneberg

  • Stefan Söderberg

  • Licia Iacoviello

  • Francesco Gianfagna

  • Susana Sans

  • Giovanni Veronesi

  • Barbara Thorand

  • Annette Peters

  • Hugh Tunstall-Pedoe

  • Frank Kee

  • Veikko Salomaa

  • Renate B Schnabel

  • Kari Kuulasmaa

  • Stefan Blankenberg

  • Christoph Waldeyer

  • Wolfgang Koenig

  • on behalf of the BiomarCARE investigators

  • June 12, 2025

  • 0 min

Share

Clinical Scorecard: The Relationship Between Lipoprotein (a) Levels and New Cases of Coronary Heart Disease: The Role of Traditional Cardiovascular Risk Factors in the Community

At a Glance

CategoryDetail
ConditionCoronary Heart Disease (CHD)
Key MechanismsElevated Lipoprotein (a) [Lp(a)] is an LDL-like particle with pro-inflammatory properties, genetically determined, contributing independently to atherosclerotic cardiovascular disease (ASCVD) risk.
Target PopulationGeneral population free of CHD at baseline, stratified by traditional cardiovascular risk factor burden.
Care SettingPrimary prevention in community and population-based cohorts.

Key Highlights

  • High Lp(a) levels (≥90th percentile, ≥43.2 mg/dL) are associated with increased incident CHD risk independent of traditional cardiovascular risk factor burden.
  • Individuals with low traditional risk (0/1 CVRF) and elevated Lp(a) have a comparable relative CHD risk to those with ≥2 CVRFs and high Lp(a).
  • Current mitigation of Lp(a)-associated risk relies on intensive control of traditional modifiable cardiovascular risk factors; specific Lp(a)-lowering therapies are under investigation.

Guideline-Based Recommendations

Diagnosis

  • Measure Lp(a) levels to identify individuals at elevated genetic risk for ASCVD.
  • Interpret elevated Lp(a) in the context of total absolute cardiovascular risk derived from traditional risk factors.

Management

  • Focus on sufficient reduction of traditional modifiable cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia, smoking) to mitigate Lp(a)-associated CHD risk.
  • Await results from ongoing phase III trials to guide Lp(a)-targeted therapies.

Monitoring & Follow-up

  • Regular cardiovascular risk assessment incorporating Lp(a) and traditional risk factors.
  • Monitor effectiveness of risk factor modification in individuals with elevated Lp(a).

Risks

  • Elevated Lp(a) confers increased CHD risk even in individuals with low traditional risk factor burden.
  • Challenges exist in mitigating Lp(a)-associated risk in very low risk populations due to limited therapeutic options.

Patient & Prescribing Data

CHD-free individuals from general population cohorts stratified by traditional cardiovascular risk factors.

Intensive management of traditional cardiovascular risk factors reduces absolute CHD risk in patients with high Lp(a); specific Lp(a)-lowering treatments are not yet available but are under clinical investigation.

Clinical Best Practices

  • Assess Lp(a) levels in primary prevention to identify genetically elevated ASCVD risk.
  • Interpret Lp(a) results alongside traditional cardiovascular risk factors to guide risk stratification.
  • Prioritize aggressive modification of modifiable risk factors in patients with elevated Lp(a), regardless of baseline traditional risk.
  • Educate patients about the genetic nature of Lp(a) and the importance of controlling modifiable risk factors.
  • Stay informed on emerging Lp(a)-targeted therapies pending results from ongoing cardiovascular outcome trials.

References

Original Source(s)

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • by Natalie Arnold, Alina Goßling, Benjamin Bay, Jessica Weimann, Christopher Blaum, Fabian J Brunner, Marco M Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters, Hugh Tunstall-Pedoe, Frank Kee, Veikko Salomaa, Renate B Schnabel, Kari Kuulasmaa, Stefan Blankenberg, Christoph Waldeyer, Wolfgang Koenig, on behalf of the BiomarCARE investigators

  • June 12, 2025

Related Content

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

Optimizing Food-Is-Medicine Programs for High Blood Pressure

Abnormal active myocardial relaxation by dipyridamole stress test in suspected early-stage heart failure with preserved ejection fraction: a retrospective exploratory analysis